These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 1493934)

  • 21. [Clinical use of hematopoietic growth factors].
    Robak T
    Pol Tyg Lek; 1992 Apr 20-27; 47(16-17):365-8. PubMed ID: 1279638
    [No Abstract]   [Full Text] [Related]  

  • 22. Dose-dense chemotherapy for primary breast cancer.
    Kümmel S; Rezai M; Kimmig R; Schmid P
    Curr Opin Obstet Gynecol; 2007 Feb; 19(1):75-81. PubMed ID: 17218856
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors.
    Savarese DM; Hsieh C; Stewart FM
    J Clin Oncol; 1997 Aug; 15(8):2981-95. PubMed ID: 9256143
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic outcomes associated with the use of hematopoietic growth factors.
    Glaspy JA
    Oncology (Williston Park); 1995 Nov; 9(11 Suppl):93-105. PubMed ID: 8608062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Haemopoietic growth factor and dose intensity in high-grade and intermediate-grade lymphoma.
    Pettengell R; Crowther D
    Ann Oncol; 1994; 5 Suppl 2():133-41. PubMed ID: 7911317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Re: Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy.
    Mayordomo JI; Rivera F; Diaz-Puente MT; Lianes P; Cortes-Funes H
    J Natl Cancer Inst; 1993 Aug; 85(15):1251-3. PubMed ID: 8331689
    [No Abstract]   [Full Text] [Related]  

  • 27. Do haemopoietic growth factors increase the efficacy of aggressive therapy of ANLL in elderly patients?
    Mandelli F; Petti MC
    Hematol Oncol; 1993; 11 Suppl 1():9-11. PubMed ID: 7683626
    [No Abstract]   [Full Text] [Related]  

  • 28. [What are the treatment possibilities for myelodysplastic syndrome?].
    von Wichert P
    Internist (Berl); 1995 Jan; 36(1):74-5. PubMed ID: 7883535
    [No Abstract]   [Full Text] [Related]  

  • 29. Hematopoietic growth factors in cancer chemotherapy.
    Lieschke GJ; Foote M; Morstyn G
    Cancer Chemother Biol Response Modif; 1997; 17():363-89. PubMed ID: 9551221
    [No Abstract]   [Full Text] [Related]  

  • 30. [Clinical use of hematopoietic growth factors].
    Gianni AM; Bregni M; Siena S; Tarella C; DiNicola M; Bonadonna G
    Haematologica; 1991 Jun; 76 Suppl 3():3-10. PubMed ID: 1752526
    [No Abstract]   [Full Text] [Related]  

  • 31. [General principles of dose-effect relationship].
    Borg C; Trillet-Lenoir V
    Bull Cancer; 2001 Sep; 88(9):833-4. PubMed ID: 11604354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Dose intensity in anticancer chemotherapy. Paris, 19 December 1994].
    Droz JP; Maraninchi D
    Bull Cancer; 1995; 82 Suppl 1():1s-2s. PubMed ID: 7626848
    [No Abstract]   [Full Text] [Related]  

  • 33. Hematopoietic growth factors in cancer chemotherapy.
    Morstyn G; Foote M; Lieschke GJ
    Cancer Chemother Biol Response Modif; 1996; 16():295-314. PubMed ID: 8639388
    [No Abstract]   [Full Text] [Related]  

  • 34. Ninth Biannual Report of the Cochrane Haematological Malignancies Group--focus on hematopoietic growth factors.
    Skoetz N; Weingart O; Monsef I; Bauer K; Brillant C; Herbst C; Kluge S; Engert A;
    J Natl Cancer Inst; 2009 May; 101(9):E1. PubMed ID: 19401542
    [No Abstract]   [Full Text] [Related]  

  • 35. Increasing chemotherapy in small-cell lung cancer: from dose intensity and density to megadoses.
    Crivellari G; Monfardini S; Stragliotto S; Marino D; Aversa SM
    Oncologist; 2007 Jan; 12(1):79-89. PubMed ID: 17227903
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal delivery of dose in cancer chemotherapy with the support of haematopoietic growth factors.
    Trillet-Lenoir V; Arpin D; Brune J
    Eur J Cancer; 1993; 29A Suppl 5():S14-6. PubMed ID: 8260260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Managing hematologic toxicities.
    Capo G; Waltzman R
    J Support Oncol; 2004; 2(1):65-79. PubMed ID: 15330374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relative dose intensity: improving cancer treatment and outcomes.
    Lenhart C
    Oncol Nurs Forum; 2005 Jul; 32(4):757-64. PubMed ID: 15990905
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current role of chemotherapy protectors in cancer treatment.
    Cáceres W; Báez L; Aponte I; Rodríguez N; Maldonado A
    Bol Asoc Med P R; 1997; 89(10-12):184-8. PubMed ID: 9577052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The therapeutic use of hematopoietic growth factors.
    Costa JJ
    J Allergy Clin Immunol; 1998 Jan; 101(1 Pt 1):1-6. PubMed ID: 9449493
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.